| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2022 | 87.39% | BTIG | $10 → $11 | Maintains | Buy |
| 08/24/2021 | 223.68% | Stephens & Co. | → $19 | Initiates Coverage On | → Overweight |
| 08/24/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/24/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/24/2021 | 206.64% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 08/24/2021 | 274.79% | BTIG | → $22 | Initiates Coverage On | → Buy |
MaxCyte Questions & Answers
The latest price target for MaxCyte (NASDAQ: MXCT) was reported by BTIG on August 15, 2022. The analyst firm set a price target for $11.00 expecting MXCT to rise to within 12 months (a possible 87.39% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for MaxCyte (NASDAQ: MXCT) was provided by BTIG, and MaxCyte maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MaxCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MaxCyte was filed on August 15, 2022 so you should expect the next rating to be made available sometime around August 15, 2023.
While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a maintained with a price target of $10.00 to $11.00. The current price MaxCyte (MXCT) is trading at is $5.87, which is out of the analyst's predicted range.